Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Background The childhood-onset cerebral form of X-linked adrenoleukodystrophy, a demyelinating disorder of the central nervous system, leads to a vegetative state and death within 3-5 years once clinical symptoms are detectable. The hypothesis to be tested was whether bone-marrow transplantation can over an extended period of time halt the inexorable progressive demyelination and neurological deterioration. Methods 12 patients with childhood onset of cerebral X-linked adrenoleukodystrophy have been followed for 5-10 years after bone-marrow transplantation. Magnetic resonance imaging (MRI), neurological, neuropsychological, electrophysiological, and plasma very-long-chain fatty acid (VLCFA) measurements were used to evaluate the effect of this treatment. Findings MRI showed complete reversal of abnormalities in two patients and improvement in one. One patient showed no change from baseline to last follow-up. All eight patients who showed an initial period of continued demyelination stabilised and remained unchanged thereafter. Motor function remained normal or improved after bone-marrow transplantation in ten patients. Verbal intelligence remained within the normal range for 11 patients. Performance (non-verbal) abilities were improved or were stable in seven patients. Decline in performance abilities followed by stability occurred in five patients. Plasma VLCFA concentrations decreased by 55% and remained slightly above the upper limits of normal. Interpretation 5-10-year fol…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“So far, the only proven therapy available for X-ALD, at least the CCALD phenotype, is bone marrow transplantation (45,46).”
From Functional overlap between ABCD1 (ALD) and ABCD2 (ALDR) transporters: a therapeutic target for X-adrenoleukodystrophy (2004) · cites this paper as [46]
In the citing paper
“Early-stage treatment of childhood cerebral ALD with hematopoietic stem cell transplantation and, more recently, gene therapy can arrest disease progression if performed in the window of opportunity when the MRI is abnormal but neurological symptoms are not yet apparent [7,38,43,44,45,46,47,48,49,50].”
From Structure and Function of the ABCD1 Variant Database: 20 Years, 940 Pathogenic Variants, and 3400 Cases of Adrenoleukodystrophy (2022) · cites this paper as [46]
In the citing paper
“Patients displaying mild neurological impairment along with discernible MRI involvement appear to achieve the most favorable outcomes (46, 47).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [46]
In the citing paper
“Allogenic hematopoietic cell transplantation (HCT) has the potential to arrest the progression of the disease in individuals with inflammatory cerebral involvement.”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [46]
In the citing paper
“However, as neurological impairment does not improve after HCT, an early diagnosis would allow for surveillance of cerebral disease and reduce potential residue (46).”
From X-linked adrenoleukodystrophy and primary adrenal insufficiency (2023) · cites this paper as [46]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Wechsler Intelligence Scale for Children
(2018) · The SAGE Encyclopedia of Intellectual and Developmental Disorders · doi:10.4135/9781483392271.n537 · Cited by 4,109
Wechsler Intelligence Scale for Children
Park, S. E., & Demakis, G. J. (2017) · Encyclopedia of Personality and Individual Differences · doi:10.1007/978-3-319-28099-8_1035-1 · Cited by 1,309
Putative X-linked adrenoleukodystrophy gene shares unexpected homology with ABC transporters
Mosser, J., Douar, A.-M., Sarde, C.-O., Kioschis, P., Feil, R., Moser, H., Poustka, A.-M., Mandel, J.-L., & Aubourg, P. (1993) · Nature · doi:10.1038/361726a0 · Cited by 1,202
Self-citationWechsler Preschool and Primary Scale of Intelligence--Revised
Wechsler, D. (2018) · PsycTESTS Dataset · doi:10.1037/t48859-000 · Cited by 1,200
Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy
Moser, H. (1997) · Brain · doi:10.1093/brain/120.8.1485 · Cited by 478
Self-citationAubourg, P., Blanche, S., Jambaqué, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.-O., Debré, M., Chaussain, J.-L., Griscelli, C., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222607 · Cited by 366
Self-citationAdrenoleukodystrophy: a scoring method for brain MR observations.
(1994) · PubMed Central · Cited by 321
Self-citationGene redundancy and pharmacological gene therapy: Implications for X-linked adrenoleukodystrophy
Kemp, S., Wei, H.-M., Lu, J.-F., Braiterman, L. T., McGuinness, M. C., Moser, A. B., Watkins, P. A., & Smith, K. D. (1998) · Nature Medicine · doi:10.1038/3242 · Cited by 249
Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation
Shapiro, E. G., Lockman, L. A., Balthazor, M., & Krivit, W. (1995) · Journal of Inherited Metabolic Disease · doi:10.1007/bf00710053 · Cited by 245
Self-citationA Two-Year Trial of Oleic and Erucic Acids (“Lorenzo's Oil”) as Treatment for Adrenomyeloneuropathy
Aubourg, P., Adamsbaum, C., Lavallard-Rousseau, M.-C., Rocchiccioli, F., Cartier, N., Jambaque, I., Jakobezak, C., Lemaitre, A., Boureau, F., Wolf, C., et al. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291101 · Cited by 242
Self-citation
Research works printed but not linked: 1
- Moser, 1999, Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls, Ann Neurol, 45, 100, 10.1002/1531-8249(199901)45:1<100::AID-ART16>3.0.CO;2-U · doi:10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u
Cited by
Hematopoietic Stem Cell Gene Therapy with a Lentiviral Vector in X-Linked Adrenoleukodystrophy
Cartier, N., Hacein-Bey-Abina, S., Bartholomae, C. C., Veres, G., Schmidt, M., Kutschera, I., Vidaud, M., Abel, U., Dal-Cortivo, L., Caccavelli, L., et al. (2009) · Science · doi:10.1126/science.1171242 · Cited by 1,508
Self-citationMoser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Self-citationHematopoietic stem-cell gene therapy for cerebral adrenoleukodystrophy
Eichler, F., Duncan, C., Musolino, P. L., Orchard, P. J., De Oliveira, S., Thrasher, A. J., Armant, M., Dansereau, C., Lund, T. C., Miller, W. P., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1700554 · Cited by 604
Self-citationEngelen, M., Kemp, S., de Visser, M., van Geel, B. M., Wanders, R. J., Aubourg, P., & Poll-The, B. (2012) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-7-51 · Cited by 562
“, when affected boys or men have no or minor symptoms due to cerebral demyelinating disease [81,82].”
Self-citationPeters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374
“We oppose it for the following reasons: (1) noninvasive neuroimaging and neuropsychological studies now permit early detection of cerebral involvement in asymptomatic patients; (2) although the risk is low, HCT is still associated with mortality; (3) HCT in boys with early cerebral disease has excellent outcomes; and…”
BackgroundMethodInfluentialSelf-citation
Metadata
- Authors
- Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., Ziegler, R., Crittenden, M., Ris, D., Berg, B., Cox, C., Moser, H., Fischer, A., & Aubourg, P.
- Affiliations
- University of Minnesota (US)
- Inserm (FR)
- University of California, San Francisco (US)
- Cincinnati Children's Hospital Medical Center (US)
- Hôpital Necker-Enfants Malades (FR)
- Kennedy Krieger Institute (US)
- Corresponding author
- Shapiro, E
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-08
- Volume
- 356
- Issue
- 9231
- Pages
- 713-718
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W2112446544
- Cited by
- 329
- References
- 33
- Citations by year
- 2026: 5 · 2025: 9 · 2024: 17 · 2023: 10 · 2022: 8 · 2021: 12 · 2020: 6 · 2019: 14 · 2018: 15 · 2017: 15 · 2016: 16 · 2015: 10 · 2014: 7 · 2013: 16 · 2012: 7
- FWCI
- 6.67
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ns029099-05)
- National Institute of Neurological Disorders and Stroke (NS 29099)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- X-linked adrenoleukodystrophy, bone marrow transplantation, demyelination, long-term follow-up, very long chain fatty acids, motor function, neuropsychological outcomes, demyelinating disease
- MeSH terms
- Adrenoleukodystrophy, Child, Child, Preschool, Fatty Acids, Humans, Intelligence, Magnetic Resonance Imaging, Male, Retrospective Studies, Severity of Illness Index, Time Factors, Bone Marrow Transplantation, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. https://app.cochat.ai/papers/10.1016/s0140-6736(00)02629-5
- The paper
- Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., Ziegler, R., Crittenden, M., Ris, D., Berg, B., Cox, C., Moser, H., Fischer, A., & Aubourg, P. (2000). Long-term effect of bone-marrow transplantation for childhood-onset cerebral X-linked adrenoleukodystrophy. The Lancet. https://doi.org/10.1016/s0140-6736(00)02629-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.